• Age ≥18 years and ≤75 years

• Histologically confirmed metastatic colorectal adenocarcinoma

• BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or NGS)

• Disease progression after at least one line of treatment: FOLFOX/XELOX (oxaliplatin-based doublet) ± bevacizumab or FOLFOXIRI (irinotecan-based triplet) ± bevacizumab. Note: Irinotecan must not have failed during prior treatment, and disease must not have progressed within three months of stopping treatment

• Patients who have received first-line treatment with cetuximab combined with a BRAF inhibitor (e.g., encorafenib, dabrafenib, vemurafenib) are allowed

• At least one measurable lesion according to RECIST v1.1 criteria

• Adequate hematologic unction: Platelets \> 90 × 10⁹/L; Hemoglobin \> 100 g/L; White blood cells \> 3 × 10⁹/L; Neutrophils \> 1.5 × 10⁹/L; Adequate liver function; Total bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases present); Alkaline phosphatase ≤ 2.5 × ULN; No ascites; Coagulation: PT ≤ 1.5 × ULN, INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN, Albumin ≥ 30 g/L

• Adequate renal function: CrCl ≥ 50 mL/min or serum creatinine ≤ 1.5 × ULN

• Liver function Child-Pugh class A

• ECOG performance status 0-1

• Expected survival \> 3 months

• Signed written informed consent

• Willing and able to comply with follow-up until death, study completion, or study termination

• For women of childbearing potential: Negative serum pregnancy test within 14 days prior to treatment; Willing to use medically accepted contraception during the study and for 3 months after the last dose

• For male participants with partners of childbearing potential: Must have undergone surgical sterilization, or use effective contraception during the study and for 3 months after the last dose